CASE STUDY 2Parents’ experiences of an Adverse EventFollowing Immunisation in South Australia – aqualitative studyEffective systems are required to monitor vaccinesafety <strong>and</strong> to provide ongoing support for those whoexperience an Adverse Event Following Immunisation(AEFI). This study aimed to better underst<strong>and</strong> theexperience <strong>and</strong> implications for parents when theirchild suffers an AEFI. Semi-structured interviewswere conducted in the homes of 10 parents whosechild had an AEFI reported during April 2005.Most parents were aware of the risk of commonside effects following immunisation however werenot aware of adverse reactions. Although they hadreceived varying amounts of information aboutcommon side effects they believed that knowledgeabout vaccine common side effects <strong>and</strong> adversereactions is necessary to enhance the immunisationprocess.Parents’ belief in immunisation remained unchanged<strong>and</strong> they all said they would continue to vaccinatetheir children, but with an increased knowledge<strong>and</strong> heightened awareness of the risks of adversereactions. Their satisfaction with the managementof health services during <strong>and</strong> after the event wasaffected by the interest shown by health professionals<strong>and</strong> the timeliness of the service.The parents in this study were not deterred fromcontinuing their child’s vaccination schedule followingan AEFI; however their needs changed, <strong>and</strong> they nowrequire more information about adverse reactions.Delivery of a timely service by an interested healthprofessional maintained parental satisfaction with themanagement of the health services.For further information contact Susan Lewis, <strong>SA</strong>Immunisation Coordination Unit:susan.lewis@health.sa.gov.<strong>au</strong>CASE STUDY 3Uptake of varicella vaccine in South Australia – across sectional survey of parental attitudes tovaricella vaccinationVaricella (chickenpox) vaccine was licensed for usein Australia in March 2000 <strong>and</strong> was included butnot funded in the Australian St<strong>and</strong>ard VaccinationSchedule (ASVS) in 2003. This study aimed to assessthe uptake of varicella vaccine in South Australianchildren <strong>and</strong> to examine the main reasons thatdetermine a parent’s decision to have their childimmunised with varicella vaccine.A telephone survey was conducted in 2004 <strong>and</strong>data were obtained from 613 households containingchildren less than 18 years of age. Six hundred <strong>and</strong>eighty children (55.7%) had a history of varicellainfection <strong>and</strong> 446 children (42.0%) had receiveda varicella vaccine. Almost 41% of susceptiblechildren aged 18 months to two years <strong>and</strong> 30.5%aged 2-4 years have no protection against varicella.Reasons why parents decided to have their childimmunised included concern about acquiring varicella(65.6%) <strong>and</strong> inclusion of the vaccine on the ASVS(10.8%). Excluding previous varicella infection, themost common reasons cited for not having childrenimmunised included lack of knowledge about thevaccine <strong>and</strong> cost. Concern about side effects (2.3%)was reported less commonly.Four years after the registration <strong>and</strong> licensing ofvaricella vaccine <strong>and</strong> one year following inclusionof the vaccine in the ASVS there is evidence ofincomplete coverage in children in South Australia.Federal <strong>Gov</strong>ernment funding for varicella vaccineshould result in high coverage rates, as the mainreasons why parents choose not to have their childimmunised would be addressed.For further information contact Helen Marshall,University of Adelaide: helen.marshall@adelaide.edu.<strong>au</strong>28
References1. Chen R <strong>and</strong> Hibbs B. Vaccine safety: Current <strong>and</strong>future challenges. Pediatr Ann. 1998;27(7):445-455.2. Chen R, Glasser J, Rhodes P, et al. Vaccine SafetyDatalink Project: A new tool for improving vaccinesafety monitoring in the United States. Pediatrics.1997;99(6):765-773.3. National Centre for Immunisation Research <strong>and</strong>Surveillance of Vaccine Preventable <strong>Diseases</strong>(NCIRS). <strong>Communicable</strong> <strong>Diseases</strong> Intelligence:Vaccine preventable diseases <strong>and</strong> vaccinationcoverage in Australia, 1999-2000. Canberra: AGPS;2002.4. Chen R. Vaccines risks: real, perceived <strong>and</strong>unknown. Vaccine.1999;17 (Suppl 3):S41-S46.5. National Institute of <strong>Public</strong> <strong>Health</strong> <strong>and</strong> Environmentin the Netherl<strong>and</strong>s (RIVM). Adverse events followingimmunisation under the national vaccinationprogramme of the Netherl<strong>and</strong>s: Number V11 -Reports in 2000. Bilthoven: RIVM; 2002.6. Gangarosa E, Galazka A, Wolfe C, et al. Impact ofanti-vaccine movements on pertussis control: theuntold story. Lancet. 1998;351:356-361.7. Ada G <strong>and</strong> Isaacs D. Vaccination: The facts, the fears,the future. St Leonards: Allen & Unwin,; 2000.8. Andrews N, Miller E, Taylor B, et al. Recall bias,MMR, <strong>and</strong> <strong>au</strong>tism. Arch Dis Child. 2002;87:493-494.9. Ellenberg SS. Safety considerations for new vaccinedevelopment. Pharmacoepidemiol Drug Saf. 2001;10(5):411-415.10. ProMed Mail 6/8/200111. Gillray, J. The Cow Pock-or-the-Wonderful Effects ofthe New Inoculation! <strong>Public</strong>ations of ye Anti-VaccineSociety. June 12, 1802. Available from:http://www-micro.msb.le.ac.uk/Tutorials/Pox/Pox13.html12. Schieferdecker CC. Dr. C. G. G. Nittinger’s Evils ofVaccination. Philadelphia: the editor, 1856. Availablefrom: http://www.sc.edu/library/spcoll/nathist/jenner2.html13. National <strong>Health</strong> <strong>and</strong> Medical Research Council(NHMRC). The Australian Immunisation H<strong>and</strong>book.7th ed. Canberra: AGPSl 2000.14. Brewer T <strong>and</strong> Colditz G. Postmarketing surveillance<strong>and</strong> adverse drug reactions: Current perspectives <strong>and</strong>future needs. JAMA. 1999;281(9):824-829.15. Jacobson R, Adegbenro A, Pankratz V, et al. Adverseevents <strong>and</strong> vaccination - the lack of power <strong>and</strong>predictability of infrequent events in pre-licensurestudy. Vaccine. 2001;19:2428-2433.16. DeStefano F. The Vaccine Safety Datalink project.Pharmacoepidemiol Drug Saf. 2001;10:403-406Ggg.17. Murphy T, Gargiullo P, Massuodi M, et al.Intussusseption among infants given oral rotavirusvaccine. N Engl J Med. 2001;344:564-572.18. Gold M <strong>and</strong> Kempe A. Adverse Events FollowingImmunisation (AEFI) in Australia: Surveillance<strong>and</strong> management. Adelaide: <strong>SA</strong> ImmunisationCoordination Unit; 2001.19. Department of <strong>Health</strong> <strong>and</strong> Ageing, TherapeuticGoods Administration. Adverse Drugs Reaction Unit.[Last updated 1/07/02, accessed 23/9/05]. Availablefrom: http://www.tga.gov.<strong>au</strong>/adr/20. Wattigney W, Mootrey G, Br<strong>au</strong>n M, et al.Surveillance of poliomyelitis vaccine adverse events,1991 to 1998: Impact of a sequential vaccinationschedule of inactivated poliovirus vaccine followed byoral poliovirus vaccine. Pediatrics. 2001;107(5):e83.21. Chen R, Haber P, Mullen J. Surveillance of the safetyof simultaneous administration of vaccines. Ann N YAcad Sci. 1995;754:309-320.22. Andrews N. Statistical assessment of the associationbetween vaccination <strong>and</strong> rare adverse events postlicensure.Vaccine. 2002;20:S49-453.23. Turnbull F, McIntyre P, Achat H, et al. National studyof adverse reactions after vaccination with BacilleCalmette-Guérin. Clin Infect Dis. 2002;34:447-453.24. Dugdale, S. Adverse events in South AustralianChildren, 1997-2002. Master of <strong>Public</strong> <strong>Health</strong> Thesis.University of Adelaide; 2003.25. Lawrence G, Menzies R, Burgess M, etal. Surveillance of adverse events followingimmunisation: Australia 2000-2002. Commun DisIntell. 2003;27:307-323.26. Zhou W, Pool V, Isk<strong>and</strong>er J, et al. Surveillancefor safety after immunization: Vaccine AdverseEvents Reporting System (VAERS) - United States,1991-2001. Morbidity <strong>and</strong> Mortality Weekly Report(MMWR). 2003;52:1-24.27. National Institute of <strong>Public</strong> <strong>Health</strong> <strong>and</strong> Environmentin the Netherl<strong>and</strong>s (RIVM). Adverse events followingimmunisation under the national vaccinationprogramme of the Netherl<strong>and</strong>s: Number V11 -Reports in 2000. Bilthoven: RIVM; 2002.28. Hull B, Lawrence G, MacIntyre CR, McIntyre P.Immunisation Coverage: Australia 2001. Canberra:Commonwealth Department of <strong>Health</strong> <strong>and</strong> Ageing;May 2002.29